Evidence map›Paper›PMID 25342043›Full record

ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2014

[Research progress of HGF/MET signaling pathway in EGFR-TKI resistance 
in non-small cell lung cancer].

Shilong Song, Minghong Bi

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Shilong SongDepartment of Medical Oncology, the First Affiliated Hospital of Bengbu Medical University, Bengbu 233004, China.
Minghong BiDepartment of Medical Oncology, the First Affiliated Hospital of Bengbu Medical University, Bengbu 233004, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is one of the most common malignant tumors of the world, and non-small cell lung cancer (NSCLC) makes up about 80%. The hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (MET) signal pathway has pleiotropic effects on many biological processes. However, aberrant HGF/MET signal pathway activation has been observed in many tumor types, and promotes cellular proliferation and metastasis via growth factor receptors and other oncogenic receptor pathways. In recent years, aberrant HGF/MET signal pathway activation has been considered a key step of resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy. This review addresses how aberrant HGF/MET signal pathway activation being associated with drug resistance to EGFR-TKI therapy in NSCLC patients.

Indexed as

Drug Resistance, NeoplasmCarcinoma, Non-Small-Cell LungErbB ReceptorsHepatocyte Growth FactorHumansLung NeoplasmsProtein Kinase InhibitorsProto-Oncogene Proteins c-metSignal TransductionErbB ReceptorsHepatocyte Growth FactorProtein Kinase InhibitorsProto-Oncogene Proteins c-met

Identifiers

PMID25342043
PMCPMC6000405
OpenAlexW1598456512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.